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Objective. To identify the frequency of obesity and metabolic complications in child and adolescent users of risperidone. Potential
associations with clinical parameters and SNPs of the HTR2C, DRD2, LEP, LEPR, MC4R, and CYP2D6 genes were analyzed.
Methods. Samples from 120 risperidone users (8–20 years old) were collected and SNPs were analyzed, alongside assessment of
chronological and bone ages, prescribed and weight-adjusted doses, use of other psychotropic drugs, waist circumference, BMI
𝑧-scores, blood pressure, HOMA-IR index, fasting levels of serum glucose, insulin, cholesterol, triglycerides, transaminases, and
leptin. Results. Thirty-two (26.7%) patients were overweight and 5 (4.2%) obese. Hypertension was recorded in 8 patients (6.7%),
metabolic syndrome in 6 (5%), and increased waist circumference in 20 (16.7%). The HOMA-IR was high for 22 patients (18.3%),
while total cholesterol and triglycerides were high in 20 (16.7%) and 41 (34.2%) patients, respectively. SNP associations were found
for LEP,HTR2C, and CYP2D6 with BMI; CYP2D6 with blood pressure, ALT, and HOMA-IR;HTR2C and LEPR with leptin levels;
MC4R and DRD2 with HOMA-IR; HTR2C with WC; and LEP with ALT. Conclusions. Although not higher than in the general
pediatric population, a high frequency of patients was overweight/obese, with abnormalities in metabolic parameters and some
pharmacogenetic associations.
1. Introduction
Risperidone, a serotonin-dopamine antagonist, is effective
in preventing delusions and hallucinations in addition to
impulsive and aggressive behavior [1, 2]. The US Food and
Drug Administration has approved the use of risperidone in
children to treat irritability related to autism (5–16 years old),
manic or mixed state in bipolar disorder (10–17 years old),
and schizophrenia (13–17 years old) [3]. However, the off-
label use of risperidone to treat a series of other behavioral
symptoms including developmental and disruptive disorders
is not uncommon [4].
Although widely prescribed, risperidone use has some
risks and few studies have evaluated its pharmacokinetic
effects in children and adolescents or adverse drug reactions
in these populations [4]. The possibility of weight gain,
cardiovascular effects, and metabolic effects associated with
hepatotoxicity, insulin and leptin resistance, hyperglycemia,
and hyperinsulinemia is associated with increased cardiovas-
cular and cancer morbimortality in adulthood [5, 6].
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Regarding the weight gain and metabolic effects induced
by risperidone, the HTR2C, DRD2, LEP, LEPR, MC4R, and
CYP2D6 genes are believed to be involved. Considering that
serotonin receptors directly influence the satiety and appetite
control systems [6], the X-linkedHTR2C gene is likely to play
an important role as it encodes the serotonin 2C receptor [7].
Another gene involved in weight gain is the DRD2
gene, which encodes the dopamine D2 receptor [8] and is
associated with obesity [9]. It has been reported that the
availability of striatal dopamine D2 receptors is significantly
reduced in overweight individuals [9].
The LEP and LEPR genes, which encode leptin and
its receptor, respectively, have also been reported to be
important in antipsychotic-induced weight gain studies [10].
Secreted only by the adipose tissue, leptin inhibits food intake
and increases energy expenditure [3, 11].
Melanocortin-4 Receptor (MC4R) is a transmembrane G
protein-coupled receptor expressed in the central nervous
system, primarily in the hypothalamus [11, 12].MC4R plays a
critical role in the regulation of energy homeostasis by leptin,
and heterozygousmutations in the gene account for 0.5–6.3%
of severe or early-onset obesity cases, which represent the
most frequent cause ofmonogenic human obesity syndromes
[6].
The gene coding the P450 2D6 enzyme (CYP2D6) is
one of the best studied pharmacogenes [13]. Approximately
25% of all drugs, including risperidone, are metabolized
through this enzyme, which also happens to be one of the
most polymorphic enzymes with over 100 known allelic
variants [13]. It is now known that polymorphisms in the
CYP2D6 gene can result in a range of effects from complete
loss of enzyme activity through deletion of the gene (poor
metabolizer status), or extensive activity, through duplication
of the gene (ultra-rapid metabolizer status) [13]. Besides the
involvement of other genes in the pharmacodynamics of
risperidone, pharmacokinetic studies have hypothesized that
low activity of the cytochrome complex may be associated
with an increase in serum risperidone levels, which can
indirectly lead to weight gain [1, 5, 14].
The aims of this study were to assess the frequency of obe-
sity, hypertension, metabolic syndrome, insulin resistance,
and dyslipidemia in a sample of child and adolescent users
of risperidone, to evaluate associations with clinical and
pharmacological data and with certain polymorphisms of the
HTR2C, DRD2, LEP, LEPR,MC4R, and CYP2D6 genes.
2. Subjects and Methods
2.1. Study Design and Participants. This was a cross-sectional
study, with a sample composed of patients attending the
psychiatric outpatient service of the hospital of the University
of Campinas (Unicamp) aged 8–20 years old and undergo-
ing treatment with risperidone for mental and behavioral
disorders. Inclusion criteria were (a) not being overweight
or obese (BMI less than +1 standard deviation (SD) for age
and sex) and not having any other illness or use of drugs
known to predispose to obesity or metabolic syndrome at the
beginning of the study; (b) not having mental or behavioral
disorders due to physical ailments; (c) not being a user of
psychoactive substances; (d) not having been diagnosed with
severe intellectual disability; (e) no diagnosis of an eating
disorder; and (f) in the case of women, not pregnant, nursing,
or using hormonal contraception. Only patients who freely
gave informed consent (or their guardians) were included in
the study.
2.2. Methods
2.2.1. Clinical Evaluation. The following data were evaluated:
gender (male or female), chronological age, bone age (TW2
20-bone method) [15], period of time of treatment with
risperidone (24months before the study at the most), current
dose of risperidone, use of other psychoactive drugs, weight
(kg, measured with a calibrated digital scale balance), height
(m, measured with a stadiometer), waist circumference (cm,
measured at the level of the umbilical scar), and systolic and
diastolic blood pressure (BP in mmHg, measured with pedi-
atric cuffs and with values adjusted for the arm diameters).
The BMI (kg/m2) was calculated and transformed into a 𝑧-
score [16]. BMI 𝑧-scores, also called BMI standard deviation
scores, are clinical measures of relative weight adjusted for
a child or an adolescent age and sex [17]. Given its age, sex,
BMI, and an appropriate reference standard, a BMI 𝑧-score
(or its equivalent BMI-for-age percentile) can be determined
[17]. In this study, the external reference used was the one
established by theWHO [16, 17]. Obese patients were defined
as having 𝑧-scores of at least +2 SD and overweight patients
as having a 𝑧-score of at least +1 SD but less than +2 SD [16].
A high waist circumference was defined as ≥90th percentile
for age, sex, and ethnicity [18]. Hypertension was defined fol-
lowing the National Heart, Lung and Blood Institute criteria,
correlated with percentiles specific to sex, height, and age
[19].
2.2.2. Laboratory Evaluation. Serum glucose, total choles-
terol, LDL, HDL, triglycerides (enzymatic colorimetric
method), insulin (immunofluorometric assay), aspartate
aminotransferase (AST), alanine transaminase (ALT) (ultra-
violet optimized kinetic method), leptin (enzyme-linked
immunosorbent assay), thyroid-stimulating hormone (TSH)
(chemiluminescence), and free thyroxin (T4) (chemilumi-
nescence) levels were assessed in the Human Physiology
Laboratory of University of Campinas clinical hospital after
12 hours of fasting. Thyroid hormone levels were measured
to exclude patients with hypo- or hyperthyroidism.
The relationship between insulin and fasting glucose
levels was used to calculate the Homeostatic Model Assess-
ment of Insulin Resistance (HOMA-IR), which is considered
normal when ≤2.89 [20]. The normal levels for serum lipids
were triglycerides <75mg/dL in children up to nine years of
age, and<90mg/dL from ten years onwards; HDL cholesterol
>45mg/dL; LDL cholesterol<110mg/dL; and total cholesterol
<170mg/dL [21]. The criteria for the diagnosis of diabetes
mellitus were fasting blood glucose level ≥126mg/dL [22].
The diagnosis of metabolic syndrome was based upon the
International Diabetes Federation criteria, including both
clinical and laboratory parameters: abdominal obesity (waist
circumference ≥90th percentile for patients under 16 years
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old and, for those aged 16 years old or more, waist circum-
ference ≥94 cm for males or ≥80 cm for females) and two
or more of the other four demanded indexes (triglycerides
≥150mg/dL; HDL-cholesterol <40mg/dL; blood pressure
≥130/85; and fasting glycemia ≥100mg/dL): [23].
Genomic DNA was extracted from total venous blood
by proteinase K lysis (Boehringer Mannheim, Germany).
The following single nucleotide polymorphisms (SNPs) were
determined in the HumanGenetics Laboratory of theMolec-
ular Biology and Genetic Engineering Center, Unicamp, by
real-time polymerase chain reaction (PCR), according to the
TaqMan allelic discrimination assay (Applied Biosystems,
Foster City, CA, USA): HTR2C: SNP rs6318 (c.68G>C;
p.Cys23Ser) and rs3813929 (c.-759C>T); LEP: SNP rs7799039
(-2548A>G);LEPR: SNP rs1137101 (c.668A>G, p.Gln223Arg);
DRD2: SNP rs1799978 (c.-241A>G) and rs6277 (C957T);
MC4R: SNP rs17782313 (3󸀠 region of the gene); CYP2D6: SNP
rs72552269 (c.100C>T, p.Pro34Ser, allele CYP2D6∗10).
The amplification reactionswere performed in a 7500 Fast
Real-Time PCR System (Applied Biosystems, Foster City, CA,
USA). The total volume of all reactions was 7 𝜇L, containing
TaqMan Genotyping PCR Master Mix 2x (3.5 𝜇L), SNV
Genotyping Assay 40x (0.175 𝜇L), MiliQ water (2.325 𝜇L), and
10 ng of each genomic DNA (1 𝜇L). Data were recorded and
analyzed using 7500 System Sequence Detection Software©
(SDS). The reactions were performed in 96-well optical
plates (0.1mL MicroAmp, Applied Biosystems, Foster City,
CA, USA) and submitted to the following temperatures and
cycles: 10min denaturation at 95∘C, 40 cycles of 15 seconds at
95∘C, and 1min extension at 60∘C.
Ancestry Characteristics of the Patients. Racial miscegenation
is highly prominent in Brazil because Europeans of white skin
color, Africans of black skin color, Asians of yellow skin color,
and indigenous peoples of Brazil participated in the process
of the formation of this country [24]. The mixing has been
intense since the beginning of colonization [24]. The small
number of white women among the Portuguese colonizers
led the latter to have relationships with native indigenous
and black slaves [24]. This mixing gave rise to other groups
such as “mulattos” (the mix of white and black), “caboclo,” or
“mameluco” (the mix of white and indigenous peoples), and
the “cafuzo” (the mix of black and indigenous peoples) [24].
Pena et al. showed recently that in Brazil one cannot predict
the color of persons from their genomic ancestry [24].
As a result, miscegenation in Brazil is an aspect that must
always be considered in any study using racial analysis [25].
The analysis adopted by Instituto Brasileiro de Geografia e
Estatistica (IBGE) has been considered as official since 1991
for racial classification in demographic studies [25]. This
classification uses self-declaration in the collection of data,
that is, the person chooses from a list of five racial categories
(white, black, mulatto, yellow, and indigenous peoples) [25].
The IBGE defines individuals who declare themselves as
mulatto or black as “black” [25].
2.3. Statistical Analysis. Statistical analysis was carried out
using SPSS version 22 (IBM Co., Armonk, NY, USA). Chi-
square or Fisher’s exact test was used to assess the presence
or absence of obesity, WC increase, hypertension, HOMA-
IR changes and triglyceride concentrations, and cholesterol
(total and fractions), in relation to sex, and any combination
of these with the concomitant use of other psychoactive
drugs, compared to that found in each SNP. To assess corre-
lations between age, BMI, BP, prescribed dose of risperidone,
medication usage time, and the continuous distribution of
routine laboratory assessments, the Spearman correlation
coefficient was used. To compare clinical and laboratory
biochemical and physiological parameters in relation to the
studied SNPs and nutritional status, the Kruskal-Wallis and
Mann-Whitney tests were applied. Significance was consid-
ered to be 𝑝 = 0.05.
3. Results
The sample consisted of 120 participants (81.7%males) with a
mean age of 13 ± 3.1 years. The majority had an externalizing
disorder and received 0.04 ± 0.03mg/kg/day of risperidone.
Among the biochemical and hormonal parameters, only AST
and leptin levels were statistically different when analyzed by
gender: AST levels were greater in males (𝑝 = 0.009; Mann-
Whitney test) while leptin was higher in females (𝑝 = 0.0001;
Mann-Whitney test).
Risperidone monotherapy was being used by 32 (26.7%)
patients. In 49 (40.9%) patients, another psychotropic drug
was being used in combination with risperidone; two psy-
chotropic drugs in 30 (25%) patients; and three or more
psychiatric drugs in 9 (7.5%) patients. The psychiatric
drugs used in association with risperidone were antide-
pressants in 53 (60.2%) patients; psychostimulants in 27
(30.7%); clonidine in 19 patients (21.6%); anticonvulsants in
11 (12.5%); lithium carbonate in 6 (6.8%); benzodiazepines in
8 (9.1%); nonbenzodiazepine sedative drugs (promethazine,
methotrimeprazine, or pericyazine) in 7 (8%); other atypical
antipsychotics in 6 (6.8%); and biperiden in 1 patient (1.1%).
There was no statistically significant difference in
the occurrence of obesity, altered WC, hypertension, or
metabolic syndrome in relation to sex, or whether or not
the user was receiving risperidone monotherapy (Table 1).
Metabolic syndrome was present in one (20%) obese case
and in five (15.6%) of overweight cases. No patient had hypo-
or hyperthyroidism.
There was no difference between the sexes regarding
values recorded for HOMA-IR index (𝑝 = 0.122, Fisher’s
exact test), increased LDL cholesterol (𝜒2 = 2.187; 𝑝 =
0.139), total cholesterol increase (𝜒2 = 1.295; 𝑝 = 0.255),
HDL cholesterol reduction (𝜒2 = 0.028; 𝑝 = 0.868), or
increased triglycerides (𝜒2 = 1.526; 𝑝 = 0.217). There was no
statistical difference between patients receiving risperidone
monotherapy or risperidone in combinationwith other drugs
in relation to HOMA-IR index (𝜒2 = 2.339; 𝑝 = 0.126),
triglyceride levels (𝜒2 = 0.001; 𝑝 = 0.977), total cholesterol
(𝜒2 = 0.512; 𝑝 = 0.474), HDL (𝜒2 = 1.364; 𝑝 = 0.243), and
LDL (𝜒2 = 0.017; 𝑝 = 0.898).
Clinical and laboratory parameters and nutritional status
are shown in Table 2. There was a correlation between the
dose of risperidone with dose per kilogram of body weight
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Table 1: Frequency of clinical or laboratory abnormalities in the 120
child and adolescent users of risperidone assessed by the study.
Abnormalities 𝑛 (%)
Overweight 32 (26.7)
Obese 5 (4.2)
Diabetes mellitus 0
BP∗ 8 (6.7)
Metabolic syndrome 6 (5)
Increased waist circumference§ 20 (16.7)
HOMA-IR changes 22 (18.3)
Total hypercholesterolemia 32 (26.7)
Hypercholesterolemia 29 (24.2)
Hypocholesterolemia 40 (33.3)
Hypertriglyceridemia 41 (34.2)
BP, blood pressure; HOMA-IR, homeostatic model assessment of insulin
resistance.
∗16 (13.3%) subjects were classified as prehypertensive; §44 (36.7%) subjects
were classified as being between the 75th and 90th percentiles for waist
circumference.
(𝑟 = 0.850, 𝑝 = 0.0001), chronological age (𝑟 = 0.260;
𝑝 = 0.004), bone age (𝑟 = 0.305; 𝑝 = 0.001), and medica-
tion usage time (𝑟 = 0.357; 𝑝 = 0.0001). There was
positive correlation between age and WC, SBP, and DBP,
and a negative correlation with AST. Positive correlation was
observed between bone age and WC, SBP, DBP, HOMA-IR
index, and negative correlation between bone age and HDL
and AST. Positive correlations were also seen between dose
of risperidone and SBP, and DBP (Table 3), with negative
correlation between the risperidone dose per kilogram of
body mass and leptin. There were no significant correlations
between duration of use of risperidone and the clinical and
laboratory parameters evaluated (Table 3). Categorical vari-
ables related to clinical and laboratory changes, evaluated in
relation to the distribution of the alleles of the evaluated SNPs,
are shown in Table 4, while comparisons for continuous
variables are shown in Table 5.
4. Discussion
The study revealed that the leptin concentrations (Table 4)
had significant genetic associations: heterozygotes (C/T) for
SNP rs3813929 in the HTR2C gene had higher serum leptin
concentrations than hemizygous C/- or T/- (in males) or
homozygous (C/C or T/T in female patients). This associ-
ation, however, was not sustained when the analysis was
separated by gender.McCarthy et al. have previously reported
an association between leptin concentrations and a different
SNP of the HTR2C gene [26].
In this study, SNP rs6318 from the HTR2C gene was
associated with not being eutrophic when risperidone was
being used, which was more frequent in carriers of the G
allele, although this association was not maintained when
the analysis was separated by gender. In female patients, the
condition of being heterozygous (C/L) was associated with
an increasedWCwhen compared with homozygotes (C/C or
G/G). Lett et al. suggest that, since previous negative studies
related to this gene have involved long periods of risperidone
usage, it is likely that theHTR2C gene is involvedwith adverse
effects that occur at the start of antipsychotic therapy [5].This
is consistent with the findings of our own study, where the
average time of drug use was more than 1.5 years [5].
Leptin has beneficial effects on glucose metabolism,
acting on the hypothalamus with an antidiabetic effect, and
its increased concentration suggests a resistance to its effects
[22]. Its association with the HTR2C gene may be linked
to the fact that this gene also has been described as being
involved in weight gain induced by antipsychotic drugs [5, 6,
10]. It is possible that, even in patients that have not yet shown
weight gain, leptin resistance has developed. Whether or not
this is the case warrants further investigation.
The presence of the T allele of rs17782313 SNP of the
MC4R gene was associated with higher HOMA-IR index
levels. The MC4R receptor, encoded by the MC4R gene, is
important in the leptin pathway although it is not directly
involved [12].Thefindings of our study suggest that theMC4R
gene may indeed play a role in leptin modulation. Although
in this study the MC4R gene was not associated with BMI,
Willer et al. [27] performed a meta-analysis of 15 genome-
wide association studies (GWAS) for BMI, comprising 32,387
participants and followed up top signals in 14 additional
cohorts comprising 59,082 participants [27]. They strongly
confirmed previous reports of association withMC4R at SNP
rs17782313 with a per-allele change in BMI of 0.20 and an
overall 𝑝 value of 1.1 × 10−20 [27].
The SNP rs7799039 of the LEP gene, when the A allele
was absent, was associated with a higher frequency of obesity.
The presence of the G allele was associated with higher levels
of ALT, which is a common finding in obesity-related hepatic
steatosis [28]. This finding agrees with the results found by
Templeman et al. [29] but differs from the negative findings
from Ferna´ndez et al. [30] and the opposite result found by
Wu et al. [31], in which studies weight gain was described
in those patients with the A allele. According to Shen et al.,
these contradictory findingsmay be due to ethnic differences,
with the A allele being a risk factor in Asian populations but a
protective factor in European populations [32]. The absence
of the A allele of SNP rs1137101 from the LEPR gene, which
encodes the leptin receptor, was associatedwith higher serum
concentrations of leptin. In the present study, it was found
most elevated in homozygous A/A subjects.
Considering the CYP2D6 gene, the absence of the C
allele (T/T genotype) was associated with increased weight
and the occurrence of hypertension. Homozygosity (C/C
and T/T) was associated with a higher HOMA-IR, and the
presence of the C allele was associated with higher ALT
values. Indeed,CYP2D6 is currently the only gene included in
the pharmacogenomic biomarker frame labeling developed
by the FDA for risperidone, with attention being given to
poor metabolizers [33].
In contrast to the findings of this study, Melkersson et al.
have reported that theCYP2D6 gene is not directly associated
with a greater frequency of hypertension and values of
HOMA-IR index change [34]. However, our findings do
agree with those of Lane et al., in which fewer patients
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Table 2: Mean values and SD of clinical and laboratory parameters in relation to total assessments and nutritional status.
Parameter Total Eutrophic Overweight Obese 𝑝#
(𝑛 = 83) (𝑛 = 32) (𝑛 = 5)
Prescribed dose% (mg/day) 2.1 ± 1.3 2.0 ± 1.3 2.4 ± 1.3 2.1 ± 1.4 0.250
Adjusted dose%% (mg/Kg) 0.04 ± 0.03 0.05 ± 0.03 0.04 ± 0.02 0.03 ± 0.02 0.343
Time used (months) 25.9 ± 27.2 24.7 ± 27.6 29.0 ± 27.0 27.4 ± 24.9 0.369
Age (years) 13.0 ± 3.1 12.9 ± 2.9 13.5 ± 3.6 10.7 ± 3.1 0.176
Bone age (years) 13.0 ± 3.1 13.0 ± 3.1 13.3 ± 3.2 10.9 ± 3.0 0.305
WC (cm) 75.4 ± 11.5 70.8 ± 9.3 86 ± 9.0§ 84.5 ± 9.2∗ <0.001
SBP (mmHg) 102.5 ± 11.8 100.6 ± 10.3 106.6 ± 12.6§ 108 ± 21.7 0.080
DBP (mmHg) 63.5 ± 11.3 62.1 ± 11.1 67.5 ± 10.8§ 62 ± 14.8 0.078
Glycemia (mg/mL) 85.2 ± 8.5 84.2 ± 7.7 86.7 ± 8.5 93.6 ± 15.0 0.120
Insulin (nUI/mL) 9.4 ± 9.8 7.5 ± 8.3 14.2 ± 12.0§ 10.1 ± 8.1 0.003
HOMA-IR index 2.0 ± 2.3 1.6 ± 2.1 3.0 ± 2.5§ 2.5 ± 2.0 0.002
Total cholesterol (mg/dL) 156.2 ± 35.9 151.4 ± 31.2 164.0 ± 43.7 184.6 ± 40.7 0.096
LDL cholesterol (mg/dL) 87.5 ± 29.1 82.8 ± 26.2 96.4 ± 33.2§ 107.0 ± 31.1 0.045
HDL cholesterol (mg/dL) 52.7 ± 14.1 53.9 ± 14.9 48.7 ± 12.0 57.4 ± 5.9 0.119
Triglycerides (mg/dL) 80.3 ± 45.4 73.9 ± 38.6 93.5 ± 56.8 101.0 ± 55.7 0.081
AST (U/L) 23.4 ± 10.0 23.4 ± 10.9 22.8 ± 6.7 28.2 ± 12.4 0.475
ALT (U/L) 18.4 ± 16.9 16.5 ± 17.0 21.1 ± 11.8§ 31.4 ± 33.0 0.001
Leptin (pg/mL) 26.0 ± 16.4 19.2 ± 12.7 40.8 ± 13.6§ 44.3 ± 8.5∗ <0.001
WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure.
#Kruskal-Wallis test.
§Statistically significant difference (by Mann-Whitney test) between overweight and normal weight.
∗Statistically significant difference (by Mann-Whitney test) between obese and normal weight individuals (𝑝 = 0.05).
%Total prescribed risperidone.
%%Prescribed dose of risperidone, but adjusted per kg of body weight.
using risperidone were C/C in genotype than those that
were C/T or T/T [35]. Correia et al. have also reported that
associations between the CYP2D6 gene and weight gain are
most pronounced among poor risperidonemetabolizers [14].
Many SNP variants of the DRD2 gene have been asso-
ciated with weight gain induced by antipsychotics [36, 37].
In this study, there were no specific associations of the two
researched DRD2 SNPs with weight gain, but both were
associated with HOMA IR. To the best of the authors’
knowledge, this association has not been previously reported.
Among the biochemical andhormonal laboratory param-
eters investigated, a gender difference was only observed for
leptin concentrations and AST values, which are physiologi-
cally expected to be higher and lower, respectively, in females.
In boys, leptin concentrations decrease and AST increases
during puberty due to a greater gain of lean mass over fat.
For females, the opposite occurs because girls gain body fat
during puberty, resulting in increased leptin concentrations
[38].
Thirty-seven (30.9%) children and adolescents were
overweight or obese, a higher proportion than the general
Brazilian population in the same age group, where 21.7% of
male adolescents and 19.4% of females are overweight [39].
At present, obesity is viewed as a pandemic that accounts for
about three million deaths annually worldwide [40].
Metabolic syndrome was found in six (5%) subjects:
proportionally slightly higher than that reported in the
Third National Health and Nutrition Examination Survey
(NHANES III) which recorded metabolic syndrome in 4.2%
of adolescents aged 12–19 years [41] and 9.2% assessed
by a study that also used data from adolescents form
NHANES III but with another cut-off [42]. While Cook et
al. (2003) adopted the parameters established by the National
Cholesterol Education Program Adult Treatment Panel III
(NCEP/ATP III) [21, 41]; the other adapted the definition
according to age [21, 42]. In the present study, we used the
criteria defined by IDF [23]. Tavares-Giannini et al. (2014)
conducted a study of obese or overweight adolescents only
(𝑛 = 232) from a public school in Rio de Janeiro [43] and
compared both criteria. They found metabolic syndrome in
40.4% and 24.6% of obese adolescents and 9.4% and 1.9%
of overweight adolescents using the NCEP/ATPIII and IDF
criteria, respectively [21, 23, 43].These findings show that the
IDF criteria, as a result of being more restrictive, may not
consider the totality of children and adolescents at increased
risk for developing diabetes and cardiovascular disease [43].
Nevertheless, in this study, occurrence was greater than in the
study of Tavares-Giannini et al. where the same criteria were
used in a population with similar characteristics, except for
the use of risperidone [43].
A high frequency of dyslipidemia with both high levels
of total cholesterol and triglyceride was found, which is
in accordance with the literature [42, 44]. The occurrence
of dyslipidemia in this sample was higher, confirming the
potential influence of risperidone in such changes [42].
Besides weight gain, child and adolescent risperidone users
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Table 3: Values of Spearman correlation test and significance level (𝑝) between clinical and laboratory parameters with age, duration of use,
and dose of risperidone in the study sample.
Parameters ChronologicAge(years)
Bone age
(years)
Length of risperidone
use (months)
Risperidone
dose (mg)
Dose (mg) per kilogram
of body weight
BMI −0.015(0.872)
0.017
(0.851)
0.026
(0.781)
0.090
(0.327)
−0.217
(0.017)
WC (cm) 0.395(0.0001)
0.409
(0.0001)
0.030
(0.746)
0.217
(0.017)
−0.151
(0.100)
SBP (mmHg) 0.487(0.0001)
0.501
(0.0001)
0.202
(0.027)
0.203
(0.027)
−0.080
(0.386)
DBP (mmHg) 0.335(0.0001)
0.308
(0.001)
0.176
(0.055)
0.126
(0.169)
−0.041
(0.658)
Total cholesterol (mg/dL) −0.008(0.928)
−0.051
(0.580)
−0.068
(0.462)
0.119
(0.194)
0.075
(0.415)
LDL cholesterol (mg/dL) 0.057(0.537)
−0.007
(0.940)
−0.037
(0.687)
0.075
(0.414)
0.008
(0.932)
HDL cholesterol (mg/dL) −0.171(0.062)
−0.183
(0.046)
−0.138
(0.133)
0.024
(0.791)
0.120
(0.193)
Triglycerides (mg/dL) 0.126(0.170)
0.147
(0.108)
−0.023
(0.806)
0.115
(0.213)
−0.25
(0.784)
HOMA-IR index 0.169(0.065)
0.185
(0.043)
0.021
(0.818)
0.088
(0.340)
−0.092
(0.320)
AST (U/L) −0.322(0.0001)
−0.283
(0.002)
0.009
(0.925)
−0.070
(0.450)
0.043
(0.644)
ALT (U/L) 0.019(0.840)
0.017
(0.858)
−0.023
(0.801)
0.100
(0.277)
−0.013
(0.889)
Leptin (pg/mL) 0.113(0.217)
0.087
(0.345)
−0.045
(0.624)
−0.012
(0.898)
−0.257
(0.005)
WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure.
seem more sensitive than adults to adverse metabolic effects,
particularly lipid abnormalities [45].
No patient was found to have glucose levels above
126mg/dL. Lower rates of diabetes than those found in adults
taking antipsychotics is easily explained by the shorter follow-
up time of young people continuously using the medication,
and by the fact that diabetes mellitus and cardiovascular
complications are correlated with age and the duration of the
presence of cardiovascular risk factors [45]. The HOMA-IR
index was abnormal in 18.3% of the patients, and this is in
agreement with other studies that have reported increased
HOMA-IR among children and adolescents using risperi-
done [41]. This index can reflect not only early pancreatic
damage, since the product is composed of glucose and
insulin, but also liver damage that may be caused by excess
lipids and evaluated using ALT levels [20].
Waist circumference (WC), which was increased in 16.7%
of the patients, is a good early indicator of metabolic dis-
orders. It has also been reported, even after adjusting for
age, to be significantly higher in children with abnormal
glucose metabolism, hyperinsulinemia, and high HOMA-IR
[46]. WC is a simple and sensitive way to determine the risk
of developing metabolic syndrome in children treated with
second-generation antipsychotics [44].
WC and blood pressure and systolic and diastolic levels
were positively correlated with age. AST values, as expected
[47], correlated negativelywith age.This is in accordancewith
the physiological increase expected with the growth foreseen
in anthropometric age curves for thesemeasurements [18, 21].
Higher leptin levels found in children with higher doses
of risperidone per kilogram of body weight may suggest
that these children are in the early stages of developing
leptin intolerance. Higher HOMA-IR values in patients with
increased bone age point to a potential risk of developing type
2 diabetes mellitus.
Among the limitations of this study, the fact that it
was a transversal study did not allow access to clinical and
laboratory parameters before treatment, so it was unable to
establish causal relationships. However, the design of the
SNP portion of the study was not inappropriate since genes
determine predisposition.
Studies of candidate gene analysis are important for
advances in pharmacogenetics. Nevertheless, newer tech-
niques for analyzing the human genome have accelerated
greatly the knowledge on this field [13]. These include
genome-wide association studies and the so-called next-
generation sequencing methods, which refer to the whole
genome and to the whole exome sequencing [13]. These
techniques are still less available and more expensive, but
they enable precise, fast, and effective research of multiple
possible SNPs underpinning traits and drug responses or
adverse effects [13]. However, despite all these advantages,
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Table 4: Absolute and relative frequencies (%) of alleles of SNPs for the presence or absence of clinical and laboratory changes evaluated as
discrete variables (𝑛 = 120).
Genotype 𝜒2 𝑝
Obese LEP
AA AG GG
Yes — — 5 (10.9) 8.393 0.015§§No 16 (100) 58 (100) 41 (89.1)
Obese LEP
Presence of allele A Absence of allele A
Yes — 5 (10.9) 8.393 0.007∗
No 74 (100) 41 (89.1)
Obese or overweight CYP2D6
CC CT TT
Yes 25 (32.5) 7 (19.4) 5 (71.4) 7.695 0.021§§No 52 (67.5) 29 (80.6) 2 (28.6)
Obese or overweight CYP2D6
Presence of allele C Absence of allele C
Yes 32 (28.3) 5 (71.4) 5.744 0.028∗
No 81 (71.7) 2 (28.6)
Obese or overweight HTR2C rs3813929 (Both genders)
Presence of allele G Absence of allele G
Yes 33 (35.1) 4 (15.4) 3.714 0.054§No 61 (64.9) 22 (84.6)
Obese or overweight Females
Presence of allele G Absence of allele G
Yes 8 (47.1) — 3.697 0.115∗
No 9 (52.9) 5 (100)
Obese or overweight Males
Presence of allele G Absence of allele G
Yes 25 (32.5) 4 (19) 1.426 0.289§No 52 (67.5) 17 (81)
HOMA-IR DRD2 rs1799978
AA AG GG
Changed 12 (13.2) 10 (34.5) — 6.661 0.010§§Normal 79 (86.8) 19 (65.5) —
HOMA-IR DRD2 rs6277
Presence of allele T Absence of allele T
Changed 6 (10.9) 16 (24.6) 3.738 0.053§Normal 49 (89.1) 49 (75.4)
Hypertension CYP2D6
CC CT TT
Yes 3 (3.9) 3 (8.3) 2 (28.6) 6.509 0.039§§No 74 (96.1) 33 (91.7) 5 (71.4)
Abdominal circumference HTR2C rs6318 (both genders)
C, CC CG G, GG
Increased 1 (3.8) 3 (42.9) 16 (18.4) 6.720 0.035§§Normal 25 (96.2) 4 (57.1) 71 (81.6)
Females
CC CG GG
Increased — 2 (40) — 7.480 0.024§§Normal 5 (100) 3 (60) 12 (100)
Males
C G
Increased 1 (4.5) 17 (22.4) 3.615 0.066∗
Normal 21 (95.5) 59 (77.6)
§Chi-square (GL = 1); §§Chi-square (GL = 2); ∗Fisher’s exact test.
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Table 5: Average rank (Mann-Whitney test) of continuous variables evaluated in relation to the SNP alleles (𝑛 = 120).
SNP Parameter 𝑛 Average Rank 𝑝
Leptin
HTR2C rs3813929 (both genders) Hemi/homozygous 115 59.17 0.044
Heterozygotes 5 91.20
HTR2C rs3813929 (females) Heterozygotes 5 9.10 0.704
Homozygous 17 12.21
HTR2C rs3813929 (males) Hemizygous C 85 48.16 0.232
Hemizygous T 13 58.27
LEPR Presence of allele A 93 57.04 0.043
Absence of allele A 27 72.41
ALT
LEP Absence of allele G 16 44.84 0.053
Presence of allele G 104 62.91
CYP2D6 Absence of allele C 113 58.60 0.016
Presence of allele C 7 91.14
HOMA-IR
MC4R Absence of allele T 7 35.14 0.047
Presence of allele T 113 62.07
CYP2D6 Heterozygotes 36 56.38 0.032
Homozygous 84 62.27
it should be considered that, in none of these methods, the
concordance between genotype and phenotype is absolute
[13]. The phenotypes can also be influenced by conditions
such as drug-drug interactions, age, sex, and comorbid
conditions [13].
Because of logistical limitations, this study was unable
to collect data such as metabolic rate, calorie intake, and
physical activity as well as the serum levels of risperidone
and its active metabolite, 9-hydroxy-risperidone. It is worth
noting that none of the studies reviewed here have assessed
these variables, making them worthy of future investigation.
Although many of the patients in this study were not on
monotherapy with risperidone and several other psychiatric
drugs can influenceweight gain andmetabolic complications,
more than a quarter of the sample did not use other drugs,
and there was no difference in the prevalence of obesity,
altered AC, hypertension, and metabolic syndrome between
groups.
5. Conclusion
In summary, the results show that a high frequency of child
and adolescent users of risperidone have metabolic disorders
and/or are overweight, despite being given therapeutic doses
considered to be suitable for their age. There were correla-
tions between age and risperidone dose with AC, SBP, and
triglyceride concentrations and between patients’ age and
DBP, insulin, AST, and leptin levels.
In the analyzed sample, it is clear that many children and
adolescents do not use risperidone as a monotherapy which
increases the risk of adverse effects. Some SNPs analyzedwere
associated with adverse effects of risperidone. The results
highlight the importance of clinical, metabolic, and genetic
factors in adverse responses to a medication widely used
in child and adolescent psychiatry. Future pharmacogenetic
studies will help further identify risk factors and facilitate
advances in individualizing antipsychotic treatment and the
development of therapeutic tools with better safety and
tolerability profiles.
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